Agentic GenMolVS

Generative Molecules & Virtual Screening
From In‑Silico Exploration to Agentic Drug Discovery Execution

See it in action

Move Beyond Virtual Screening. Toward Agentic Drug Discovery

Virtual screening has reduced experimental load in early-stage drug discovery. But hit-to-lead optimization and candidate prioritization remain fragmented, manual and slow.

That is where Persistent GenMolVS creates value.

It brings together generative AI, deep learning–based structure prediction and agentic workflows to help life sciences teams move from isolated in‑silico experiments to autonomous, execution‑ready computational drug discovery.

What GenMolVS Delivers
GenMolVS is an AI‑powered generative drug discovery accelerator, built on NVIDIA BioNeMo and NeMo Agentic Toolkit to:

Transform fragmented discovery steps into an end‑to‑end pipeline

Protein structure prediction, virtual screening, molecule ranking and de‑novo molecule generation in a single workflow

Enable agentic execution across preclinical drug discovery

Autonomous screening with scientific control at decision points

Move faster from target sequence to drug‑like candidates

Adaptive AI‑driven exploration of chemical space

How GenMolVS Transforms Drug Discovery Execution

GenMolVS turns isolated in‑silico analysis into agentic, execution‑ready discovery workflows by making structure, decisions and optimization loops explicit.

From: Static docking scripts and manual molecule ranking
To: Adaptive workflows where AI agents predict protein structures, screen millions of molecules, rank candidates and optimize chemotypes with full traceability